The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
 
Jennifer Rachel Eads
Employment - Bristol-Myers Squibb (I); Janssen Oncology (I)
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene (I)
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; lexicon
Research Funding - AstraZeneca/MedImmune (Inst); Genentech (Inst); Hutchison MediPharma (Inst); Incyte; MedImmune (Inst); Oncolys BioPharma (Inst); Seagen (Inst); Tarveda Therapeutics (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I); Janssen Oncology (I)
 
Paul J. Catalano
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Regeneron (Inst)
 
George A. Fisher
Stock and Other Ownership Interests - Seagen (I)
Honoraria - Advanced Accelerator Applications; Ipsen
Consulting or Advisory Role - Ipsen; Merck; Taiho Pharmaceutical
Research Funding - Aduro Biotech (Inst); Forty seven (Inst); Genentech/Roche (Inst); Merck (Inst); Newlink Genetics (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech
Other Relationship - AstraZeneca; CytomX Therapeutics; Hutchison MediPharma; Silenseed; Taiho Pharmaceutical; Terumo Clinical Supply
 
Daniel Rubin
Consulting or Advisory Role - Roche/Genentech
Research Funding - GE Healthcare (Inst); Philips Healthcare (Inst)
Patents, Royalties, Other Intellectual Property - Several pending patents on AI algorithms (Inst)
 
Andrei Iagaru
Consulting or Advisory Role - Isotopen Technologien
Research Funding - Advanced Accelerator Applications (Inst); GE Healthcare (Inst); Progenics (Inst)
Travel, Accommodations, Expenses - GE Healthcare
 
David S. Klimstra
Employment - PAIGE.AI
 
Bhavana Konda
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Xencor (Inst)
 
Myron S. Kwong
No Relationships to Disclose
 
Jennifer A. Chan
Stock and Other Ownership Interests - Merck
Honoraria - Advanced Accelerator Applications; Ipsen
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer (I); Pfizer (I); TerSera
Research Funding - Lilly (Inst); Sanofi (Inst)
(OPTIONAL) Uncompensated Relationships - Camurus
 
Ana De Jesus-Acosta
Consulting or Advisory Role - Merck
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Thorvardur Ragnar Halfdanarson
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Crinetics Pharmaceuticals (Inst); Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Tersera; TERUMO; Viewpoint Molecular Targeting (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Agios (Inst); Basilea (Inst); Ipsen (Inst); Novartis (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst)
 
Walid Labib Shaib
Honoraria - Blueprint Medicines; BMS; Ipsen; Lexicon; Mylan; Natera
Research Funding - ArQule (Inst); Basilea (Inst); GlaxoSmithKline (Inst); Lexicon (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Lexicon
 
Heloisa P. Soares
Consulting or Advisory Role - AstraZeneca; Exelixis; Helsinn Therapeutics; Incyte; Ipsen; Pfizer; TerSera
(OPTIONAL) Uncompensated Relationships - NCCN; North American Neuroendocrine Tumor Society
 
Sung Chul Hong
No Relationships to Disclose
 
Terence Z. Wong
Consulting or Advisory Role - GE Healthcare
Research Funding - Blue Earth Diagnostics (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - GE Healthcare
 
Peter J. O'Dwyer
Consulting or Advisory Role - Genentech
Research Funding - Amgen (Inst); Array BioPharma (Inst); BBI Healthcare (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Lilly/ImClone (Inst); Minneamrita Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Syndax (Inst); syndax (Inst); Syndax (Inst); Syndax (Inst); Syndax (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - Dai-ichi Sankyo; Lilly